Introduction
============

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by dysregulation of the immune system involving the hyperactivity of T and B cells, elevated production of pathogenic autoantibodies, complement activation, and the formation of immune complexes causing multiorgan damage by deposition in host tissue \[[@B1]\]. Although the exact pathogenesis of SLE remains elusive, extremely complicated and multifactorial interactions between genetic and environmental factors are thought to contribute to the development of the disease \[[@B2]\]. Genetic variation of various genes may lead to different inflammation, immune responses and susceptibility to SLE \[[@B3]\]. Several genetic association studies have been performed in patients with SLE and various genes encoding proteins with regulatory or adaptive functions in the immune system have been considered as candidates \[[@B4],[@B5]\]. Well-established risk factors include alleles in the major histocompatibility complex, interferon regulatory factor 5, integrin alpha M, signal transducer and activator of transcription 4 and B lymphoid tyrosine kinase in genome-wide association studies in SLE \[[@B6],[@B7]\]. Many susceptibility genes fall into key pathways that are consistent with previous studies implicating immune complexes, host immune signal transduction and interferon pathways in the pathogenesis of SLE \[[@B6],[@B8]\].

Liver X receptor (LXR) alpha (*NR1H3*) and beta (*NR1H2*) can influence macrophage biology by modulation of lipid metabolism and by effects on innate immunity. The release of cytokines including interleukin (IL)-1, IL-6 and tumor necrosis factor-α from macrophages results in recruitment of monocytes and cross-talk with T cells, perpetuates cellular activation and further promotes atherosclerotic lesion development \[[@B9]\]. The anti-inflammatory effect of LXRs was first described in a study that demonstrated that LXR activation attenuated *Escherichia coli*- or lipopolysaccharide (LPS)-induced expression of pro-inflammatory molecules including IL-6, inflammatory nitric oxide synthase and cyclooxygenase-2 in macrophages from wild type mice, but not LXR null mice \[[@B10]\]. LXR is reportedly essential for macrophage survival and clearance of invading bacteria in protective immune responses \[[@B10],[@B11]\], whereas LXR activation also inhibits lymphocyte proliferation \[[@B12]\]. A recent study found that LXRs mediate the regulation of Th17 cell differentiation and autoimmunity \[[@B13]\]. However, the possible association between *LXRs* genetic polymorphisms and SLE has not been addressed.

In this study, we attempted to identify polymorphisms of the *NR1H3* and *NR1H2* genes associated with susceptibility to SLE in Koreans and to elucidate the functional effect of these polymorphisms.

Methods
=======

Study subjects
--------------

Three hundred SLE patients and 217 normal controls (NC) were enrolled from Ajou University Hospital in Suwon, Korea. All patients satisfied at least four of the 1982 revised American College of Rheumatology (ACR) criteria for SLE \[[@B14]\]. The patients' medical histories were reviewed from the onset of disease until admission to the study. Clinical features of the disease, as defined by ACR criteria, were recorded in standardized questionnaires. Information about the medical history, clinical symptoms and physical examination were registered by a rheumatologist in a database when blood sampling was done. For each patient, blood cell count, routine chemistry, urinalysis, C-reactive protein and anti-dsDNA antibody were examined. Anti-dsDNA antibody was measured by radioimmunoassay using a commercial kit (Trinity Biotech, Bray, Ireland). Clinical manifestations including oral ulcer, arthritis, serositis, rash, nephritis, leukopenia (\<4 × 10^3^ cells/μL), lymphopenia (\<1 × 10^3^ cells/μL) and thrombocytopenia (\<100 × 10^3^ cells/μL), anti-dsDNA antibody (\>7.0 IU/ml) and anti-cardiolipin antibody (either or both immunoglobulin G (IgG) \>20 GPL-U/mL and IgM positive \>20 MPL-U/mL) were defined by positive involvement when it was positive at least once during the disease duration. The NCs were chosen from the general population using a screening questionnaire, which had to indicate no history of rheumatic diseases or autoimmune disorders. Also, replication samples were collected from other SLE patients (n = 160) and NC (n = 143). All the subjects who participated in this study were ethnically Korean. The study was approved by the Institutional Review Board of Ajou University Hospital and all subjects gave their informed consent.

Identification and genotyping of SNPs
-------------------------------------

Fifty SLE patients and 50 NC Korean volunteers were used for SNP identification. Genomic DNA was extracted from whole blood using the QuickGene DNA whole blood kit S (Fujifilm Life Science, Tokyo, Japan). The *NR1H3* gene located between the promoter region and intron 2 region was amplified by polymerase chain reaction (PCR) with Amfisure PCR Master Mix (GenDEPOT, Barker, TX, USA). The *NR1H2* gene located in the promoter region and between the exon 10 region and the 3' untranslated region were amplified by PCR. We identified possible polymorphisms in the *NR1H3* and *NR1H2* genes that were screened by direct sequencing (Bionics, Seoul, Korea). A minor allele frequency ≥5% was considered to indicate a SNP. Additionally, SNP genotyping was performed using the SNaPSHOT ddNTP primer extension kit (Applied Biosystems, Foster City, CA, USA) for SLE patients (n = 250) and NC (n = 167) and replication samples (160 SLE patients and 143 NC).

Preparation of promoter constructs
----------------------------------

Six reporter structures composed of the *NR1H3* -1830 T \> C, -1003 G \> A and -115 G \> A sequence carrying each allele and the luciferase reporter gene were transfected into the Hep3B cell line. A 500 bp-sized fragment (from -2121 to -1622) of the *NR1H3* gene was PCR-amplified using either -1830 T homozygous or -1830 C homozygous genomic DNA as a template and the following primers: forward primer: 5′- CGGCGG**GGTACC**ACATCT ATGCCAGCCCTGTTTCAG -3′; the bold characters represent the KpnI site, reverse primer: 5′- CCGCCG**CTCGAG**ACTGAGCCCCAGCGGCTTTC -3′; the bold characters denote the XhoI site. A 500 bp-sized fragment (from -1266 to -767) of the *NR1H3* gene was PCR amplified using either -1003 G homozygous or -1003 A homozygous genomic DNA as a template and the following primers: forward primer: 5′- CTATCGATA**GGTACC**CTCCCCTCAGCCTTTCCCCA -3′; reverse primer: 5′- ATCGCAGAT**CTCGAG**TCCCCCTCACTC CAACACTGAG -3′. A 500 bp-sized fragment (from -374 to +126) of the *NR1H3* gene was PCR amplified using either -115 G homozygous or -115 A homozygous genomic DNA as a template and the following primers: forward primer: 5′- CTATCGATA**GGTACC**GTTTTG ACCTCAGAGGGATATTAT -3′; reverse primer: 5′- ATCGCAGAT**CTCGAG**CAGGTAATGAAGGAGGCTGA -3′. Each PCR product was subcloned separately into the KpnI--XhoI site of the pGL3-Basic luciferase reporter vector (Promega, Madison, WI, USA).

Transfection and luciferase reporter assays
-------------------------------------------

Hep3B cells (hepatocellular carcinoma cell line \#58064; Korean Cell Line Bank (KCLB), Seoul, Korea) were cultured in Roswell Park Memorial Institute (RPMI) 1640 (Invitrogen, Carlsbad, CA, USA) and COS-7 cells (African Green Monkey kidney cell line \#21651, KCLB) were cultured in high-glucose (D)MEM (Hyclone, Logan, UT, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) at 37°C in a 5% CO~2~ incubator. Hep3B and COS-7 cells were transfected by using FuGENE6 (Roche, Mannheim, Germany) according to the manufacturer's instructions. Reporter plasmid DNA of *NR1H3* 0.5 μg and pSV-β-galactosidase plasmid DNA (Promega) 0.5 μg were resuspended and further gently mixed with 1.5 μL of FuGENE6 reagents described previously \[[@B15]\]. The relative transcriptional activity of each construct was expressed as the ratio of luciferase activity to β-galactosidase activity using a luminometer, the LUMIstar OPTIMA (BMG LABTECH, Ortenberg, Germany). The transfections and luciferase assays were conducted in triplicate, and the experiments were repeated at least three times with different cell preparations as described previously \[[@B15]\].

Pharmacological treatment and reporter gene assay
-------------------------------------------------

Hep3B and COS-7 cells were transfected with *NR1H3* promoter pGL3-basic constructs using FuGENE6 (Promega) according to the manufacturer's instructions. After incubation for six hours, the medium was replenished with 500 μL of fresh medium with 20% FBS, and the cells were incubated a further 18 hours at 37°C in a 5% CO2 incubator. Twenty four hours after transfection, cells were treated with either 200 ng/mL LPS (Sigma-Aldrich, St. Louis, MO, USA), 3 μmol/L 3-\[3-\[N-(2-chloro-3-trifluoro methylbenzyl)-(2,2-diphenylethyl)amino\]propyloxy\]phenylacetic acid hydrochloride (hydrochloride GW3965; GW3965, Sigma-Aldrich) or 5 μmol/L N-(2,2,2-trifluoroethyl)-N-\[4-\[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl\]phenyl\]-benzenesulfonamide (sulfonamide T0901317; T0901317, Cayman, Ann Arbor, MI, USA) for 24 hours. These concentrations and time were chosen based on previous work \[[@B16]\].

Primary culture and Epstein-Barr virus transformation of lymphocytes
--------------------------------------------------------------------

The peripheral blood mononuclear cells were separated from peripheral blood using Histopaque (Sigma-Aldrich) and counted to provide 1 × 10^6^ cells/ml. Then, the prepared Epstein-Barr virus (EBV; B95-8 cell line) was added. After 24 hours incubation in a CO2 incubator, 0.5 μg/ml cyclosporine A was added and the cells cultured for three weeks. After one week, cell line formation was confirmed. After two weeks, adequate transformation was confirmed by phase microscopy (until medium begins to turn orange/yellow and small clumps of cells become visible). The media change step was repeated until the total cell number exceeded 5 × 10^6^ cells/ml. Finally, the transformed cells were retrieved and preserved at -80°C in a deep freezer.

Total RNA extraction and quantitative real-time RT-PCR
------------------------------------------------------

The EBV-transformed B cell line was cultured in RPMI 1640 supplemented with 10% heat-inactivated FBS at 37°C in a 5% CO2 incubator. Total RNA was extracted from B cells using a RNA mini extraction kit (Inclone, Seoul, Korea) according to the manufacturer's suggested protocol. Total RNA (2 μg) was converted to cDNA by a GoScript reverse transcription system kit (Promega) according to the manufacturer's suggested protocol. After annealing at 25°C for five minutes, extension at 42°C for one hour, inactive reverse transcriptase at 70°C for 15 minutes, the product was stored at -20°C until used.

The reverse transcription PCR (RT-PCR) reaction was performed by PCR with amfisure PCR Master Mix (GenDEPOT) under the following conditions: hot start at 94°C for four minutes followed by 37 cycles of 95°C for one minute, 58°C for one minute, and 72°C for thirty seconds with a final extension at 72°C for ten minutes. *NR1H3* was amplified with the following primers: forward primer: 5′- AGGGCTGCAAGGGATTCTTCC -3′, reverse primer: 5′- TCTGACAGCACACACTCCTCCC -3′. Samples were subjected to parallel amplification of the constitutively expressed, housekeeping gene, human β-actin using the following primers: forward primer: 5′- TCCTTCTGCATCCTGTCGGC -3′, reverse primer: 5′- CAAGAGATGGCCACGGCTGC -3′.

The real-time PCR reaction was performed by a Rotor-Gene SYBR Green PCR kit (Qiagen, Valencia, CA, USA) with the same primers of RT-PCR under the following conditions: heating to 95°C for five minutes, and 40 cycles of 95°C for five seconds, 58°C for ten seconds, and 72°C for thirty seconds.

B cell proliferation assay
--------------------------

B cells were seeded into 96-well plates at a density of 1 × 10^5^ cells. After incubation for 24 hours, cells were treated with either 200 ng/mL LPS (Sigma-Aldrich), 3 μmol/L GW3965 (Sigma-Aldrich) or 5 μmol/L T0901317 (Cayman) for 24 hours. The concentrations and time were chosen based on previous data. After incubation for 24 hours, cell viability was assessed using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega). This is a colorimetric assay containing a tetrazolium compound. When the tetrazolium is reduced, it produces a colored formazan product that is soluble in cell culture medium and is maximally absorbed at 490 nm. Assays were conducted in triplicate, and the experiments were repeated at least three times.

Nuclear extract preparation and electrophoretic mobility shift assay
--------------------------------------------------------------------

Hep3B cells were washed with ice-cold phosphate-buffered saline before being suspended in ice-cold hypoosmotic buffer comprised of 10 mM HEPES/KOH (pH 7.9), 2 mM MgCl2, 0.1 mM ethylenediaminetetraactic acid (EDTA), 10 mM KCl, 1 mM dithiothreitol (DTT), 1 mM phenylmethanesulfonylfluoride (PMSF), 1 mM NaVO3, 10 mM NaF and complete protease inhibitor cocktail (Roche, Basel, Switzerland). The cells were incubated on ice for 10 minutes and for an additional 15 minutes in the presence of 0.2% Nonidet P-40. After centrifugation at 15,000 × g for 30 seconds, the pellet was resuspended in a cold saline buffer that contained 50 Mm HEPES/KOH (pH 7.9), 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA, 10% (v/v) glycerol, 1 mM DTT, 1 mM PMSF and protease inhibitors. The mixture was incubated on ice for 30 minutes. After centrifugation at 15,000 × g for 30 minutes at 4°C, the supernatant containing the nuclear proteins was stored at -80°C until use. The following double-stranded oligonucleotides were used as probes for the electrophoretic mobility shift assay (EMSA): for *NR1H3* -1830 T \> C 5′ - AGATTTCCTA\[t/c\]CAAAGGCTCT - 3′, CdxA as a nonspecific competitor, 5′ - AGATCTGGTACCATTTAAGCCCTCGAGATCTA - 3′ and for GATA-3 as a specific competitor, 5′ - GTTATTTATCTCTTAGTTGTAGTTATTTATCTCTTGTTGTA - 3′. The double-stranded oligonucleotides were annealed by incubation at 95°C for five minutes followed by gradual cooling to room temperature. The double-stranded DNA probes were radiolabeled at their 5′-ends with DNA polymerase I (Klenow fragment; Promega) and \[α-32P\]CTP. The reaction mixtures (10 μl), which contained 5 μg of nuclear extract, 10 mM HEPES (pH 7.9), 250 ng poly(dI:dC), 0.005 mM MgCl~2~, 75 mM NaCl, 5 mM DTT, 1 mM NaNO~3~, 10 mM NaF, 1 mM EDTA, 400 ng bovine serum albumin and 50% glycerol, were preincubated on ice for 20 minutes, and then incubated for 20 minutes on ice in the presence of 0.2 pmol of radiolabeled probe. The reaction mixtures were then subjected to electrophoresis on a native 6% polyacrylamide gel. For competition experiments, unlabeled blunt-ended competitor oligonucleotides were added to the binding reaction mixtures before the addition of the radiolabeled oligonucleotide probes. The gels were dried and radioactivity was detected using a FLA3000 scanner (Fuji Photo Film, Tokyo, Japan).

Statistical analyses
--------------------

The genotype frequency was tested for significant departure from Hardy-Weinberg equilibrium at each SNP by chi-square analysis. Differences in genotype frequency between the cases and controls were tested by the chi-square test and calculation of the odds ratio (OR) and the 95% confidence interval (CI). Three logistic regression models (codominant, dominant and recessive) were used to analyze the SNP after controlling for age and sex as covariates. Differences in the mean value of the phenotypic characteristics between groups were compared by an analysis of variance (ANOVA) test and a t-test. *P* values \<0.05 were considered to be significant. Haplotypes were analyzed using Haploview version 4.2 based on the EM algorithm \[[@B17]\]. Linkage disequilibrium between loci was measured using the absolute value of Lewontin's /D′/ and *r*^*2*^\[[@B18]\]. Statistical analyses were conducted using the SPSS version 12.0 software (SPSS, Chicago, IL, USA).

Results
=======

Clinical characteristics of the study subjects
----------------------------------------------

The mean age of the SLE patients was 30.6 ± 9.2 years and 89.0% were female. The mean age of the NC was 29.8 ± 5.8 years and 88.5% were female. Clinical features of SLE patients are as follows with decreasing frequency: arthritis (67.3%), oral ulcer (49.3%), rash (39.0%), nephritis (26.3%) and serositis (13.3%). In replication samples, the mean age of the SLE patients was 42.3 ± 13.4 years and 81.3% were female. The mean age of the NC was 41.7 ± 9.7 years and 81.8% were female (Additional file [1](#S1){ref-type="supplementary-material"}).

Genotype and haplotype frequencies
----------------------------------

The allele and genotype frequencies of the *NR1H3* polymorphisms are presented in Table  [1](#T1){ref-type="table"}. Genotype distributions of all the polymorphisms satisfied the Hardy--Weinberg proportions in the NC (*P* \>0.05). Based on an allele frequency ≥5%, five SNPs of the *NR1H3* gene were identified; -1851 T \> C (rs3758673) and -1830 T \> C (rs3758674) in the promoter region, and -1003 G \> A (new), -840 C \> A (rs61896015) and -115 G \> A (rs12221497) in the intron 1 region.

###### 

**The genotype and allele frequencies of polymorphisms in the*NR1H3*gene**

  **Loci**                     **Genotype**      **Our**     **Replication**   **Combine**                                                                                                                                           
  ---------------------------- -------------- ------------- ----------------- -------------- ------------------------ -------------- -------------- ------------ ------------------------ ------------- ------------- -------------- ------------------------
  -1851 T \> C                 TT              172 (57.3%)     115 (53.0%)      co : 0.281    1.171 (0.879 \~ 1.559)    93 (58.1%)     78 (54.5%)    co : 0.578   1.107 (0.577 \~ 1.851)   265 (57.6%)   193 (53.6%)    co : 0.215    1.151 (0.921 \~ 1.438)
                               TC              112 (37.3%)     57 (40.1%)       do : 0.507    1.132 (0.786 \~ 1.630)    55 (34.4%)     53 (37.1%)    do : 0.816   1.051 (0.689 \~ 1.603)   167 (36.3%)   140 (38.9%)    do : 0.425    1.118 (0.723 \~ 2.163)
                               CC               16 (5.3%)       15 (6.9%)       re : 0.316    1.094 (0.918 \~ 1.305)    12 (7.5%)      12 (8.4%)     re : 0.557   1.071 (0.852 \~ 1.347)    28 (6.1%)     27 (7.5%)     re : 0.252    1.085 (0.944 \~ 1.246)
                               q\.                0.240           0.270           0.285       1.080 (0.938 \~ 1.245)      0.250          0.270         0.567      1.055 (0.878 \~ 1.267)      0.242         0.269         0.212       1.074 (0.960 \~ 1.201)
                               HWE                                                0.790                                                                0.487                                                              0.817                  
  -1830 T \> C                 TT              238 (79.3%)     195 (89.9%)      co : 0.001    0.431 (0.260 \~ 0.714)   131 (81.9%)    129 (90.2%)    co : 0.034   0.483 (0.246 \~ 0.948)   369 (80.2%)   324 (90.0%)   co : \<0.001   0.447 (0.299 \~ 0.668)
                               TC              58 (19.3%)      22 (10.1%)       do : 0.999     0.000 (0.000 \~ NA)      28 (17.5%)     14 (9.8%)     do : 1.000    0.000 (0.000 \~ NA)     86 (18.7%)    36 (10.0%)     do : 0.999     0.000 (0.000 \~ NA)
                               CC               4 (1.3%)        0 (0.0%)        re : 0.002    0.658 (0.507 \~ 0.855)     1 (0.6%)      0 (0.00%)     re : 0.041   0.698 (0.495 \~ 0.985)    5 (1.1%)      0 (0.0%)     re : \<0.001   0.671 (0.546 \~ 0.826)
                               q\.                0.110           0.051           0.001       0.658 (0.512 \~ 0.512)      0.090          0.050         0.038      0.706 (0.508 \~ 0.981)      0.104         0.05         \<0.001      0.672 (0.552 \~ 0.820)
                               HWE                                                0.432                                                                0.538                                                              0.318                  
  -1003G \> A                  GG              250 (83.3%)     201 (92.6%)      co : 0.002    0.396 (0.223 \~ 0.705)   139 (86.9%)    131 (91.6%)    co : 0.194   0.606 (0.285 \~ 1.289)   389 (84.6%)   332 (92.2%)    co : 0.001    0.460 (0.293 \~ 0.721)
                               GA              47 (15.7%)       16 (7.4%)       do : 0.999     0.000 (0.000 \~ NA)      21 (13.1%)     12 (8.4%)      do : NA               NA             63 (14.8%)     28 (7.8%)     do : 0.999     0.000 (0.000 \~ NA)
                               AA               3 (1.0%)        0 (0.0%)        re : 0.002    0.629 (0.468 \~ 0.847)     0 (0.0%)       0 (0.0%)     re : 0.194   0.779 (0.534 \~ 1.135)    3 (0.7%)      0 (0.0%)      re : 0.001    0.680 (0.540 \~ 0.856)
                               q\.                0.088           0.037           0.001       0.626 (0.470 \~ 0.835)      0.070          0.040         0.209      0.791 (0.549 \~ 1.140)      0.080         0.039         0.001       0.680 (0.544 \~ 0.850)
                               HWE                                                0.573                                                                0.600                                                              0.443                  
  -840 C \> A and -115G \> A   GG              235 (78.3%)     195 (89.9%)     co : \<0.001   0.408 (0.246 \~ 0.675)   131 (81.88%)   129 (90.21%)   co : 0.034   0.483 (0.246 \~ 0.948)   366 (79.6%)   324 (90.0%)   co : \<0.001   0.430 (0.288 \~ 0.642)
                               GA              61 (20.3%)      22 (10.1%)       do : 0.999     0.000 (0.000 \~ NA)      28 (17.5%)     14 (9.79%)    do : 1.000    0.000 (0.000 \~ NA)     89 (19.3%)    36 (10.0%)     do : 0.999     0.000 (0.000 \~ NA)
                               AA               4 (1.3%)        0 (0.0%)        re : 0.001    0.639 (0.493 \~ 0.829)    1 (0.63%)      0 (0.00%)     re : 0.041   0.698 (0.495 \~ 0.985)    5 (1.1%)      0 (0.0%)     re : \<0.001   0.658 (0.535 \~ 0.808)
                               q\.                0.115           0.051          \<0.001      0.642 (0.501 \~ 0.823)      0.090          0.050         0.038      0.706 (0.508 \~ 0.981)      0.108         0.050        \<0.001      0.661 (0.542 \~ 0.805)
                               HWE                                                0.432                                                                0.538                                                              0.318                  

Each *P* value was calculated with co-dominant (co), dominant (do) and recessive (re) models. Logistic regression analysis was applied to control for age and sex as covariables. Each q row's *P* value was analyzed by the Chi square test. Two genetic polymorphisms of the NR1H3 gene, -840 C \> A and -115 G \> A, were in complete linkage disequilibrium. CI, confidence interval; HWE, Hardy--Weinberg equilibrium; NA, not applicable; OR, odds ratio; q., minor allele frequency.

In the -1830 T \> C polymorphism, the genotype frequency of the minor allele was significantly higher in the SLE patients when compared to the NC (*P* = 0.001 for the co-dominant model, *P* = 0.002 for the recessive model). Also, the minor allele of the -1003 G \> A polymorphism was significantly more frequent in the SLE patients than in the NC (*P* = 0.002 for the co-dominant model, *P* = 0.002 for the recessive model). In addition, the SLE patients had the minor allele of the -115 G \> A polymorphism more frequently (*P* = \<0.001 for the co-dominant model, *P* = 0.001 for the recessive model). However, screening of the *NR1H2* gene for genetic variation did not reveal differences between the SLE and the NC (data not shown).

In the replication samples, the minor allele of the -1830 T \> C and -115 G \> A polymorphisms were significantly more frequent in the SLE patients than in the NC (*P* = 0.034 for the co-dominant model, *P* = 0.041 for the recessive model). Moreover, in combined samples, the minor allele of the -1830 T \> C and -115 G \> A polymorphisms were significantly more frequent in the SLE than in the NC (*P* = \<0.001 for the co-dominant model, *P* = \<0.001 for the recessive model). Although there was no difference in the -1003 G \> A polymorphism in replication samples, the minor allele of the -1003 G \> A polymorphism was significantly more frequent in the combined SLE patients than in the combined NC (*P* = 0.001 for the co-dominant model, *P* = 0.001 for the recessive model).

Linkage disequilibrium between SNPs and locus by locus was examined. Two genetic polymorphisms of the *NR1H3* gene, -840 C \> A and -115 G \> A, were in complete linkage disequilibrium. Therefore, -840 C \> A was excluded in the haplotype analysis. Three common haplotypes for four polymorphisms were constructed using the Haploview software: HT1 \[TTGG\], HT2 \[CTGG\] and HT3 \[TCAA\]. There was a significant difference between SLE and NC in the observed haplotype HT1 \[TTGG\] (*P* = 0.033 for the co-dominant model, *P* = 0.012 for the recessive model) and HT3 \[TCAA\] (*P* = 0.008 for the co-dominant model, *P* = 0.009 for the dominant model) (Table  [2](#T2){ref-type="table"}).

###### 

**The haplotype frequencies of*NR1H3*gene**

  **Haplotype**   **SLE**      **NC**      **SLE versus NC**                 
  --------------- --------- ------------- ------------------- -------------- -------------------------
  HT1             +/+        109 (36.3%)      103 (47.5%)     co : 0.033      0.727 (0.542 \~ 0.974)
  \[TTGG\]        +/-        169 (56.3%)      99 (45.6%)      do : 0.808      0.956 (0.681 \~ 1.349)
                  -/-         22 (7.3%)        15 (6.9%)      re : 0.012      0.796 (0.666 \~ 0.951)
  HT2             +/+         16 (5.3%)        15 (6.9%)      co : 0.255      0.847 (0.636 \~ 1.128)
  \[CTGG\]        +/-        111 (37.0%)      87 (40.1%)      do : 0.280      0.908 (0.761 \~ 1.082)
                  -/-        173 (57.7%)      115 (53.0%)     re : 0.507      0.884 (0.614 \~ 1.273)
  HT3             +/+         2 (0.7%)         0 (0.0%)       co : 0.008      2.739 (1.304 \~ 5.751)
  \[TCGG\]        +/-        30 (10.0%)        9 (4.1%)       do : 0.009      1.662 (1.134 \~ 2.435)
                  -/-        268 (89.3%)      208 (95.9%)     re : 0.999      36085.247 (0.000 \~ NA)
  HT others       +/+         3 (1.0%)         0 (0.0%)       co : \<0.001    8.375 (2.557 \~ 27.431)
                  +/-        30 (10.0%)        3 (1.4%)       do : \<0.001    2.984 (1.641 \~ 5.427)
                  -/-        267 (89.0%)      214 (98.6%)     re : 0.999      32475.263 (0.000 \~ NA)

Haplotypes (HT) were analyzed using Haploview version 4.1 based on the EM algorithm. Each *P* value was calculated with co-dominant(co), dominant(do), and recessive(re) models. Logistic regression analysis was applied to control for age and sex as covariables. Two genetic polymorphisms of the *NR1H3* gene, -840 C \> A and -115 G \> A, were in complete linkage disequilibrium. Therefore, -840 C \> A was excluded in the haplotype analysis. CI, confidence interval; NA, not applicable; OR, odds ratio.

Associations between SLE phenotype and SNPs
-------------------------------------------

The clinical characteristics according to genotype and haplotype of *NR1H3* gene are summarized in Table  [3](#T3){ref-type="table"}. In the -1830 T \> C polymorphism, arthritis was significantly more common in the SLE patients with the -1830 C allele (*P* = 0.005). Also, arthritis (*P* = 0.006), anti-dsDNA (*P* = 0.041) and triglyceride (*P* = 0.011) were more common in the SLE patients with the -1003 A allele than the -1003 G allele, but oral ulcer (*P* = 0.039) and central nervous system (CNS) involvement (*P* = 0.015) were less common in the -1003 A allele. In addition, arthritis (*P* \<0.001) was more common in the SLE patients with the -115 A allele than -115 C allele, but oral ulcer (*P* = 0.024) was less common in the -115 A allele (Additional file [2](#S2){ref-type="supplementary-material"}).

###### 

**Comparison of the clinical characteristics according to the genotype and haplotype of*NR1H3*gene in SLE**

  **Characteristics**     **-1830 T \> C**     **-1003G \> A**      **-115G \> A**                                                                                                     
  --------------------- -------------------- -------------------- ------------------ -------------------- --------------------- ----------- -------------------- --------------------- -----------
  Oral ulcer^a^             122 (51.3%)           26 (41.9%)            0.191            130 (52.0%)           18 (36.0%)          0.039        124 (52.8%)           24 (36.9%)          0.024
  Arthritis^a^              151 (63.4%)           51 (82.3%)            0.005            160 (64.0%)           42 (84.0%)          0.006        146 (62.1%)           56 (86.2%)         \<0.001
  Anti-ds DNA^a^            156 (65.5%)           47 (75.8%)            0.124            163 (65.2%)           40 (80.0%)          0.041        153 (65.1%)           50 (76.9%)          0.071
  CNS involvement^a^         19 (8.0%)             3 (4.8%)             0.295             22 (8.8%)             0 (0.0%)           0.015         20 (8.5%)             2 (3.1%)           0.106
  Triglyceride^b^           97.8 ± 64.1          112.8 ± 67.1           0.108            95.6 ± 61.5          126.9 ± 74.9         0.007        95.3 ± 62.1          120.9 ± 71.2         0.011
  **Characteristics**     **HT1 \[TTGG\]**     **HT2 \[CTGG\]**    **HT3 \[TCGG\]**                                                                                                    
                              **+/+**            **+/-, -/-**          ***P***             **+/+**            **+/-, -/-**        ***P***       **+/+, +/-**            **-/-**          ***P***
                         **n = 63 (41.7%)**   **n = 88 (58.3%)**      **value**       **n = 24 (15.9%)**   **n = 127 (84.1%)**   **value**   **n = 30 (19.8%)**   **n = 121 (80.1%)**   **value**
  Arthritis^a^               62 (56.9%)          140 (73.3%)            0.004             9 (56.3%)            193 (68.0%)         0.331         29 (90.6%)           173 (64.6%)         0.003
  Leukopenia^a^              61 (56.0%)          112 (58.6%)            0.652             11 (68.8%)           162 (57.0%)         0.356         20 (62.5%)           153 (57.1%)         0.558
  Lymphopenia^a^            100 (91.7%)          172 (90.1%)            0.628             12 (75.0%)           260 (91.5%)         0.027         30 (93.8%)           242 (90.3%)         0.526

^a^This value is presented as the number of patients positive for the feature or antibody. ^b^This value was presented as the means ± SD. Leukopenia is defined as a leukocyte count that is less than 4 × 10^3^ cells/μL. Lymphopenia is defined as the lymphocyte count that is less than 1 × 10^3^ cells/μL. Logistic regression analysis was applied to control for age and sex as covariables. No association with SLE phenotypes was observed when the other SNPs were evaluated. No association with SLE phenotypes was observed when the other haplotypes were evaluated. HT, haplotype; SLE, systemic lupus erythematosus; SNP, single nucleotide polymorphism.

The frequency of arthritis was significantly lower in patients who had haplotype HT1 \[TTGG\] (recessive model, *P* = 0.004); however, arthritis was more common in patients with HT3 \[TCGG\] (dominant model, *P* = 0.003). The frequency of lymphopenia was significantly lower in patients who had haplotype HT2 \[CTGG\] (recessive model, *P* = 0.027) (Additional file [3](#S3){ref-type="supplementary-material"}).

Transcriptional activity of the *NR1H3* gene according to the SNPs
------------------------------------------------------------------

To determine if the *NR1H3* -1830 T \> C, -1003 G \> A and -115 G \> A polymorphisms are associated with altered promoter activity, six reporter structures composed of the promoter sequence carrying each allele and the luciferase reporter gene were transfected into the Hep3B cell line. The luciferase activity of the structure containing -1830 C was less enhanced when compared to that of the structure containing -1830 T (*P* = 0.009) (Figure  [1](#F1){ref-type="fig"}A). The trend of enhanced promoter activity of the -1830 T structure is shown in different cell lines of the COS-7 cells (*P* = 0.052) (Figure  [1](#F1){ref-type="fig"}B). The luciferase activity of the structure containing -1003 A was less enhanced when compared to that of the structure containing -1003 G (*P* = 0.030) (Figure  [1](#F1){ref-type="fig"}A). The trend of enhanced transcriptional activity of the -1003 G structure is shown in different cell lines of the COS-7 cells (*P* = 0.061) (Figure  [1](#F1){ref-type="fig"}B). There were no significant differences between -115 G and -115 A in the observed luciferase activity (Figure  [1](#F1){ref-type="fig"}A, B).

![**Functional effect of the polymorphisms on transcriptional activity. (A,B)** Relative luciferase production (ratio of luciferase production driven by the reporter construct to that by the promoter-less control vector, pGL3-Basic) in Hep3B cells **(A)** and COS-7 cells **(B)**. **(C, D)** Relative luciferase production by stimulation with 200 ng/mL LPS, 3 μmol/L GW3965 and 5 μmol/L T0901317 in Hep3B cells **(C)** and COS-7 cells **(D)**. The *P* value was determined by a paired t test. \**P* \<0.05. LPS, lipopolysaccharide.](ar4563-1){#F1}

Pharmacological treatment and reporter gene assay
-------------------------------------------------

*NR1H3* transcriptional activity according to the stimulants (LPS and synthetic ligands, such as GW3965 and T0901317) was analyzed in Hep3B cells and COS-7 cells. The luciferase activity of -1830 C was less enhanced when compared to that of -1830 T in GW3965 and T0901317 treated Hep3B cells (*P* = 0.034 and *P* \<0.001, respectively) (Figure  [1](#F1){ref-type="fig"}C). The reduced enhancement of transcriptional activity of the -1830 C structure was reconfirmed in LPS- and T0901317-treated COS-7 cells (*P* = 0.023 and *P* = 0.006, respectively) (Figure  [1](#F1){ref-type="fig"}D). The luciferase activity of -1003 A was less enhanced when compared to that of -1003 G in GW3965- and T0901317-treated Hep3B cells (*P* = 0.038 and *P* = 0.004, respectively) (Figure  [1](#F1){ref-type="fig"}C). Less enhanced transcriptional activity of the -1003 A structure was replicated in GW3965- and T0901317-treated COS-7 cells (*P* = 0.029 and *P* = 0.009, respectively) (Figure  [1](#F1){ref-type="fig"}D). However, there were no significant differences between -115 G and -115 A in the observed luciferase activity in Hep3B cells and COS-7 cells treated with LPS, GW3965 and T0901317 (Figure  [1](#F1){ref-type="fig"}C, D).

Nuclear extract preparation and electrophoretic mobility shift assay
--------------------------------------------------------------------

EMSA using nuclear extracts prepared from Hep3B cells revealed a specific band with the -1830 T probe, but not with the -1830 C probe. The shifted band produced by the -1830 T probe was not visible in the presence of the nonlabeled -1830 T probe but remained visible in the presence of the nonlabeled -1830 C probe (Figure  [2](#F2){ref-type="fig"}A). A survey of a database of transcription factors suggested that the -1830 T \> C polymorphism generated a potential GATA-3 binding motif. To clarify the involvement of GATA-3, we performed a competition assay using GATA-3 and CdxA probes, and found that the shifted band corresponding to the -1830 T probe was completely competed for by the unlabeled GATA-3 probe, but not by the unlabeled CdxA probes (Figure  [2](#F2){ref-type="fig"}B). The -1830 T specific band was also competed by anti-GATA-3 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) but not supershifted (Figure  [2](#F2){ref-type="fig"}C).

![**Results of an EMSA for the -1830 T \> C polymorphism using nuclear extracts obtained from Hep3B cells. (A)** Nucleotide sequences of oligonucleotides used as probes and competitors. **(B)** Differential binding of a nuclear protein to -1830 T \> C alleles. **(C)** Identification of the transcription factor binding to 1830 T \> C probe using competitive binding assay. EMSA, electrophoretic mobility shift assay.](ar4563-2){#F2}

*NR1H3* mRNA expression according to genotype
---------------------------------------------

B cell lines were screened to measure mRNA expression of *NR1H3* gene according to the genotypes using RT-PCR. As illustrated in Figure  [3](#F3){ref-type="fig"}A, the -1830 TC type B cells displayed a lower *NR1H3* mRNA expression level than the -1830 TT type B cells in SLE. Also, the -1830 TC type B cells displayed a lower *NR1H3* mRNA expression level than the -1830 TT type B cells in NC. Moreover, the *NR1H3* expression level was significantly different between genotypes in real-time PCR. The -1830 TC type had an approximately 1.8-fold decrease compared to the -1830 TT type in SLE. Also, the -1830 TC type had an approximately 1.8-fold decrease compared to the -1830 TT type in NC (*P* = 0.03 and *P* = 0.025, respectively) (Figure  [3](#F3){ref-type="fig"}B).

![**Effect of the -1830 T \> C polymorphism on*NR1H3*mRNA expression and B cells proliferation assay. (A)** RT PCR products were separated by electrophoresis on 1% agarose gel and stained with EtBr. Gels were examined by ultraviolet illumination. **(B)** The mRNA levels were determined by quantitative-PCR normalized to β-actin mRNA expression. Each experiment was conducted in duplicate for each sample, and the results are expressed as mean ± SD for three independent experiments. The *P* value was determined by a paired t test. **(C)** The effect of the -1830 T \> C polymorphism on the *NR1H3* gene on the B cells proliferation assay. This is a colorimetric assay containing a tetrazolium compound. When the tetrazolium is reduced, it produces a colored formazan product that is soluble in cell culture medium and maximally absorbed at 490 nm. Assays were conducted in triplicate, and the experiments were repeated at least three times. Values are mean ± SD; \**P* \<0.05. **(D)** Effect of the -1830 T \> C polymorphism on the *NR1H3* gene on B cells proliferation by stimulation with 200 ng/mL LPS, 3 μmol/L GW3965 and 5 μmol/L T0901317. Values are mean ± SD. The *P* value was determined by a paired t test. \**P* \<0.05. LPS, lipopolysaccharide; SD, standard deviation.](ar4563-3){#F3}

Effect of LXR agonists on B cell proliferation according to the genotypes
-------------------------------------------------------------------------

B cell proliferation assay was performed to determine the effect of -1830 T \> C polymorphism. Proliferation of -1830 TC type was increased compared to that of -1830 TT type in B cells from SLE patients (*P* = 0.011) (Figure  [3](#F3){ref-type="fig"}C). Proliferation of the -1830 TC type was increased when compared to that of the -1830 TT type in GW3965- and T0901317-treated B cells from SLE patients (*P* = 0.040 and *P* = 0.017, respectively) (Figure  [3](#F3){ref-type="fig"}D).

Discussion
==========

In the present study, we evaluated the associations of genetic polymorphisms of the *NR1H3* and *NR1H2* with SLE in a Korean population. There were five genetic polymorphisms of the *NR1H3* gene at -1851 T \> C, -1830 T \> C, -1003 G \> A, -840 C \> A and -115 G \> A including one novel SNP (-1003 G \> A) between the promoter region and the second intron region. Also, we found that the rare alleles of the -1830 T \> C, -1003 G \> A and -115 G \> A polymorphisms were associated with a significantly higher disease susceptibility. In the haplotype analysis, there was a significant difference between SLE and NC in the observed haplotype HT1 \[TTGG\] and HT3 \[TCAA\]. Our results suggest that the human *NR1H3* gene plays an important role in the development of SLE.

Some genetic association studies of *LXR* genes have been reported in different ethnic populations and diseases, such as obesity \[[@B19]\], metabolic syndrome \[[@B20]\], type 2 diabetes \[[@B21]-[@B23]\], Alzheimer's disease \[[@B24],[@B25]\], inflammatory bowel disease \[[@B26]\] and gallstone disease \[[@B27]\]. Most studies have focused on the *NR1H2* gene and most studies have suggested that the *LXR* gene polymorphisms are associated with susceptibility and outcome of metabolic diseases.

To investigate the effects of polymorphisms on *NR1H3* expression, we used a functional assay of promoter activity in reporter structures that contained mutant type or polymorphic promoters in the Hep3B cell line and COS-7 cell line. Since the Hep3B cell line originates from human hepatocellular carcinoma and LXR is synthesized in the liver, spleen, kidney and macrophages, it was an appropriate cell line for this study. To replicate the Hep3B cell line results, we also tested the promoter activity in the COS-7 cell line from African green monkey kidney \[[@B21]\]. Additionally, the *NR1H3* transcriptional activity according to the stimulants (LPS, GW3965 and T0901317) was analyzed in Hep3B cells and COS-7 cells.

The promoter reporter structure carrying the -1830 C and -1003 A alleles displayed lower promoter activity than the structure carrying the -1830 T and -1003 G alleles in Hep3B cells and COS-7 cells. Moreover, the luciferase activity of the structure containing -1830 C and -1003 A was less enhanced when compared to that of the structure containing -1830 T and -1003 G in GW3965- and T0901317-treated cells.

The -1830 C allele, which is associated with arthritis, displayed significantly lower promoter activity. The -1003 A allele, which has been linked with oral ulcer, arthritis, anti-dsDNA, CNS involvement and triglyceride, displayed significantly lower promoter activity. These findings suggest that LXR regulates inflammatory signaling in SLE patients. It may be possible that under-expressed *NR1H3* leads to autoantibodies production which is against joints and DNA in SLE patients. Besides, the inflammation may increase levels of triglycerides which is a risk factor for atherosclerosis in lupus patients.

The frequency of arthritis was significantly lower in patients who had haplotype HT1 \[TTGG\]; however, arthritis was more common in patients with HT3 \[TCGG\]. The frequency of lymphopenia was significantly lower in patients who had haplotype HT2 \[CTGG\]. These findings suggest that the disease phenotype is more common in patients with SLE who have minor allele -1830 T \> C, -1003 G \> A and -115 G \> A polymorphisms than in those who have the major homozygous genotype. These phenotype results were consistent with the genotype results.

In particular, the -1830 T \> C promoter polymorphism was significantly different in genotype analysis and clinical manifestations. The -1830 T \> C polymorphisms were located in the promoter site, which is important for gene expression. Therefore, we focused on the functional effects of -1830 T \> C polymorphism. To determine if the genetic variants created a transcription factor binding site, sequences were submitted to the TFSEARCH online program, which revealed that the -1830 T \> C polymorphism might be a potential GATA-3 binding motif. GATA-3 belongs to the GATA family of transcription factors \[[@B28]\]. The GATA-3 transcription factor is a GATA binding protein 3 that plays a crucial role in Th1 and Th2 development. Some evidence suggests that the GATA-3 transcription factor is correlated with lupus disease activity \[[@B29],[@B30]\].

We performed an EMSA with nuclear extracts from Hep3B cells using double-stranded oligonucleotide probes that corresponded to the -1830 T \> C. This polymorphism affected a transcription factor binding in the promoter region of *NR1H3* because a shifted band was found in the presence of the -1830 T probe in the EMSA results. The transcription factor bound to the -1830 T probe was identified as GATA-3 through a competition assay, because GATA-3 was bound to the -1830 T allele promoter with a higher affinity compared with that of the 1830 C allele promoter. We also performed supershift assays using a commercially available anti-GATA-3 antibody and found that the anti-GATA-3 antibody could affect DNA-protein complex formation in the -1830 T probe. The -1830 T specific band was also competed by anti-GATA-3 antibody. Our data suggest that, in the transcription regulation of *NR1H3* gene, GATA-3 might act as a positive regulator because the -1830 T allele containing the reporter construct showed higher promoter activity than the -1830 C allele containing the reporter construct. The results of the present study indicate that the binding affinity of GATA-3 may be decreased in SLE patients who carry the -1830 C allele.

The B cell proliferation assay was performed to determine the effect of -1830 T \> C polymorphism. Proliferation of -1830 TC type was increased when compared to that of -1830 TT type in basal, GW3965- and T0901317-treated B cells from SLE patients. Also, proliferation of the -1830 TC type was increased when compared to the -1830 TT type in T0901317-treated B cells from NC. LXR agonist treated cells proliferated less than untreated cells. These findings are consistent with the results of previous studies that have shown that LXR agonist suppresses cell proliferation \[[@B31],[@B32]\].

Moreover, -1830 TC type B cells displayed a lower *NR1H3* mRNA expression level than the -1830 TT type B cells in SLE. Also, the -1830 TC type B cells displayed a lower *NR1H3* mRNA expression level than the -1830 TT type B cells in NC. These mRNA expression and proliferation assay results show that the LXR reduced proliferation of B cells from SLE patients.

In our luciferase assay and proliferation assay, LXR was activated by both T0901317 and GW3965 that has a similar tendency but the T0901317 effect was stronger than that of GW3965. These findings are consistent with the results of previous studies that have shown that activation of PXR targets may explain why T0901317 induces dramatic liver steatosis, while GW3965 has a milder effect \[[@B33]\].

Conclusions
===========

These results suggest that the *NR1H3* gene genetic polymorphisms may be associated with disease susceptibility and clinical manifestations of SLE. Especially, the -1830 T \> C polymorphism within the *NR1H3* promoter region may be involved in regulation of *NR1H3* expression.
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